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LIST OF ABBREVIATIONS  
 
ANOVA   Analysis of variance 
AGTR1    Angiotensin II receptor type 1 
CI    Confidence interval 
CKD    Chronic kidney disease 
DMSO   Dimethylsulfoxid 
ESRD    End stage renal disease 
FBS     Fetal bovine serum  
IFN-γ     Interferon-γ 
MPT    Mitochondrial permeability transition 
PI    Propidium iodide 
SD    standard deviation 
TG    Transgenic 
Thg    Thapsigargin 
TRPC5   Transient receptor potential cannel 5 
ROS    Reactive oxygen species 
Introduction 
 2 
1 INTRODUCTION 
 
Chronic kidney disease (CKD) is a major public health problem worldwide. According 
to the 2014 Center of Disease Control and Prevention estimate more than 10% of the 
US population – more than 20 million people have CKD. Studies from Europe and 
Asia show similar numbers (Levey et al., 2007). By 2030 more than 2 million 
Americans will have progressed to end stage renal disease (ESRD) (Stevens et al., 
2006), which with the use of dialysis still has a mortality rate of 20% per year or 5 
year mortality of 60-70% (Go et al., 2004). Additionally CKD is associated with a high 
risk of cardiovascular mortality to an extent that a patient with CKD is more likely to 
die due to stroke or myocardial infarction than to progress to ESRD (Agrawal et al., 
2009). 
 
1.1 Podocyte damage  
Damage to podocytes – the cells that form the filter structure in the kidney, plays a 
central role in the progression of kidney disease (Greka and Mundel, 2012b). To 
make the filtering process possible, podocytes have a highly specialized cytoskeleton 
with interdigitating foot processes that cover the blood vessels in the glomerular tufts 
– the filter units in the kidney (Pavenstadt et al., 2003). To guarantee sustained 
glomerular filter function there is a sophisticated regulatory network underlying the 
cytoskeleton in podocytes (Faul et al., 2008). The podocytes response to injury is 
characterized by a cytoskeletal rearrangement called foot process effacement. This 
rearrangement leads to breakdown of the filter structure and loss of vital blood 
proteins like albumin with the urine (Mundel and Shankland, 2002). Albuminuria 
therefore is one of the earliest and most sensitive markers of filter damage and is a 
strong and independent predictor of kidney function decline, progression of 
cardiovascular disease and all-cause mortality (Agrawal et al., 2009). Why foot 
process effacement is initiated by the podocytes as the stereotypical response to 
almost all insults is still under debate. According to one theory it is an adaptive 
strategy to protect podocytes from being lost by detachment from the glomerular tuft. 
Loss of more than 40% of its podocytes leads to irreversible destruction of the 
glomerulus called glomerulosclerosis (D'Agati et al., 2011). As podocytes cannot be 
regenerated in the adult a mechanism to protect those viable cells even at the 
expense of some filter capacity would not be surprising (Kriz et al., 2013). In 
agreement with this theory foot process effacement in it self is a reversible process 
as can be seen in minimal change disease: During active disease with massive 
proteinuria the only visible change is foot process effacement and after remission no 
difference can be detected to health kidneys. 
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1.2 The role of TRPC5 in the initiation of foot process effacement 
One of the essential steps in the initiation of foot process effacement is activation of 
the canonical transient receptor potential cannel 5 (TRPC5) (Schaldecker et al., 
2013). TRPC channels are a family of six nonselective cation channels, which are 
classically activated downstream of phospholipase C activation and generation of 
phosphatidylinositol-4,5-bisphosphate (PIP2) (Clapham, 2003). Primarily Ca2+ and 
Na+ are conducted by TRPC5 at a permeability ratio of 10:1 (Blair et al., 2009). A 
range of additional factors including membrane stretching (Lau et al., 2016) and 
oxidation (Hong et al., 2015) activates TRPC5. Thus the Ca2+ influx through TRPC5 
is the integrated result of a variety of input signals. Recent work in the Greka 
laboratory revealed that TRPC5 knock out (KO) mice are unable to initiate foot 
process effacement in response to toxic substances widely used as established 
models of acute kidney damage (Schaldecker et al., 2013). Therefore our current 
understanding is that calcium influx through TRPC5 is activating well-known 
mediators of cytoskeletal rearrangement to initiate foot process effacement 
(Clapham, 2007; Faul et al., 2008; Greka and Mundel, 2012a; Hall, 1998). 
 
The question what is causing the final progression from foot process effacement to 
ESRD remains unresolved (D'Agati et al., 2011). We hypothesized that persistent 
Ca2+ influx through sustained TRPC5 activation in a chronic disease scenario will 
finally overwhelm the podocytes Ca2+ buffering mechanisms and cause irreversible 
Ca2+ toxicity and cell death. 
 
1.3 Calcium toxicity 
Loss of Ca2+ homeostasis with sustained elevation of cytosolic Ca2+ has been known 
to cause cell death for decades (Schanne et al., 1979). Among the different 
destructive pathways that get activated by high cytosolic Ca2+ mitochondrial 
permeability transition (MPT) is often decisive in determining the lethal outcome 
(Dong et al., 2006). Rising levels of cytosolic Ca2+ often signal increased energy 
demand for the cell. Following the electrical gradient of the mitochondrial membrane 
potential Ca2+ is taken up by mitochondria. Increased free Ca2+ in the mitochondrial 
matrix stimulates oxidative metabolism matching ATP production to the increased 
demand (Pan et al., 2013; Rasola and Bernardi, 2011). A rise in oxidative 
metabolism is accompanied by a rise in reactive oxygen species (ROS) (Rasola and 
Bernardi, 2011).  If the level of mitochondrial matrix Ca2+ or ROS rises too high a 
cyclophilin D (encoded by the Ppif gene) dependent large conductance pore in the 
inner mitochondrial membrane opens (Baines et al., 2005; Nakagawa et al., 2005; 
Schinzel et al., 2005). Under physiological circumstances the reversible MPT pore 
opening seems to be an important homeostatic mechanism to deal with strong, 
transient and local fluctuations in Ca2+ concentration (Rasola and Bernardi, 2011). An 
impressive example is the inability of Ppif KO mice to deal with pressure overload 
after transaortic constriction and their high mortality in a cardiac performance test 
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called “swimming exercise” (Elrod et al., 2010). Prolonged MPT pore opening in 
consequence of sustained high cytosolic calcium or ROS leads to release of matrix 
Ca2+, loss of the mitochondrial membrane potential with termination of oxidative 
phosphorylation and mitochondrial swelling up to rupture of the outer membrane 
releasing even more cell death inducing factors (Rasola and Bernardi, 2011). Apart 
from being the critical step in ischemia reperfusion injury (Baines et al., 2005; 
Nakagawa et al., 2005; Schinzel et al., 2005) MPT also plays a decisive and 
detrimental role in chronic settings like Alzheimer’s disease (Du et al., 2008). A 
similar study in an animal model of heart failure could show that enhanced activity of 
a Ca2+ channel progresses to Ca2+ overload causing MPT, cell death and finally 
organ failure (Nakayama et al., 2007).  
 
1.4 Approach and aim of the study 
We hypothesized that sustained TRPC5 activation in a chronic kidney disease setting 
will cause Ca2+ overload with MPT leading to podocyte loss and finally kidney failure. 
Therefore we wanted to investigate if sustained pharmacological TRPC5 activation 
causes cell death in cultured podocytes with detectable signs of mitochondrial 
damage and MPT. If our hypothesis is correct TRPC5 blockade could be a new 
therapeutic strategy for kidney disease.  
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2 MATERIAL AND METHODS  
2.1 Cell culture 
Conditionally immortalized mouse podocytes were provided by Dr. P. Mundel (MGH, 
Boston, USA) and cultured as previously described (Mundel et al., 1997). In brief 
podocytes were cultured in RPMI-1640 supplemented with 10% heat inactivated fetal 
bovine serum (FBS), 100U/ml penicillin, 100µg/ml streptomycin (all gibco) and 
50U/ml mouse interferon-γ (IFN-γ) (eBioscience) at 33°C and 5% CO2 I. The cells 
were split when reaching 70% confluency. For differentiation the podocytes were 
split, thermoshifted to 37°C and cultured in RPMI-1640 supplemented with 10% heat 
inactivated fetal bovine serum (FBS), 100U/ml penicillin, 100µg/ml streptomycin (all 
gibco) without (IFN-γ) for twelve days. Media was changed every other day for 
differentiating as well as for proliferating cells. All cell culture dishes for podocytes 
were coated with type I collagen (100µg/ml in 0.02N acetic acid incubated for 1h at 
37°C). Only cultures which reached optimal confluency and showed the typical 
differentiated morphology (Shankland et al., 2007) after 12 days of differentiation 
were used for experiments.  
 
2.2 Viability assays 
2.2.1 CellTiter-Glo® Luminescent Cell Viability Assay 
Podocytes were differentiated in 96 well plates and incubated with the indicated 
concentration of Riluzole dissolved in DMSO for two or three days. Promega’s 
CellTiter-Glo® reagent was added to the cells and viability measured according to 
the manufacturers instructions. This assay uses cellular ATP to create light with 
luciferase. Therefore the detected luminescence signal is proportional to cell viability. 
All experimental conditions were performed at least in quadruplicate and the entire 
experiment was repeated three times. The data is presented as fraction of viable 
cells, with DMSO only treated set as 1.  
 
2.2.2 Annexin V / propidium iodide flow cytometry  
Annexin V – Alexa Fluor 647 conjugate and propidium iodide (PI) solution (1 mg/ml) 
were purchased from Molecular ProbesTM. Annexin V conjugates bind 
phosphatidylserine in the outer layer of the cell membrane, indicating this early 
apoptotic change. PI is an intercalating dye, which can only bind cellular DNA after 
membrane integrity is broken to indicate necrosis. Podocytes were differentiated in 6 
well plates and incubated with Riluzole and/ or ML204 as indicated. At the end of the 
experiment the cells were trypsinized, washed with PBS, stained in annexin binding 
buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4) with 4µL annexin 
V conjugate and 0.5 µL PI, kept on ice and analyzed by flow cytometry as soon as 
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possible. All flow cytometry experiments were performed on a BD LSRFORTESSA 
Flow Cytometer. Annexin V or PI positive cells were classified as dead. For each 
condition more than 90000 cells were analyzed in total in three experiments 
performed in triplicate.  
 
2.3 Mitochondrial Permeability Transition assay 
To directly measure mitochondrial permeability transition the MitoProbe Transition 
Pore Assay Kit for flow cytometry (Molecular Probes) was used according to the 
manufacturers instructions. In brief after incubating podocytes with Riluzole and/ or 
ML204 as indicated the cells were trypsinized and stained with Calcein AM and 
Cobalt in HBSS for 15min. After Calcein AM is taken up into living cells esterases 
cleave of the AM group resulting in a bright green fluorescence in all living cells. Co2+ 
quenches the Calcein fluorescence everywhere except in mitochondria, as it cannot 
penetrate through the intact mitochondrial membrane. The reagents were quenched 
by adding more HBSS, spun down, resuspended in annexin binding buffer with 
annexin V and PI and analyzed by flow cytometry as soon as possible. For each 
condition more than 450000 cells were analyzed in total in three experiments 
performed in triplicate. The data is presented as relative calcein fluorescence, with 
DMSO only treated set as 1.  
 
2.4 Reactive oxygen species detection 
CM-H2DCFDA and Mitosox were bought from Molecular Probes and used according 
to the manufacturers protocol. In brief after incubating podocytes with Riluzole the 
cells were stained with reactive oxygen species indicator and analyzed by flow 
cytometry as soon as possible. 
 
2.5 Mitochondrial morphology 
Mitochondria in differentiated podocytes were stained with MitoTracker® Red CM-
H2XRos (Molecular Probes). The dye is non-fluorescent until it gets oxidized in live 
cells and becomes covalently bound to mitochondrial proteins. Because the 
accumulation of the staining in mitochondria is mitochondrial membrane potential 
dependent we stained live podocytes before the start of the experiment. After 
incubating the cells with Riluzole as indicated, images were acquired by confocal 
microscopy from living podocytes in cell culture media with a 63X water immersion 
lens. Representative images were acquired by randomly sampling all four quadrants 
of a dish. To determine the aspect ratio (ratio of major axis to minor axis) (Yu et al., 
2006) and a value for the number of swollen mitochondria the images were quantified 
with custom written ImageJ scripts (see supplement). First, the images were 
convolved with a 7x7 Mexican hat kernel to separate closely packed mitochondria. 
The mitochondria were segmented from the background by an automated 
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thresholding procedure. ImageJ’s “analyze particles” function was used to determine 
the aspect ratio for all segmented objects above a minimum size (to control for 
background noise artifacts) or to count all swollen mitochondria defined by a 
minimum size and circularity. To verify the classification the counted objects were 
visualized separately for each image. 
 
2.6 Statistical analysis 
All statistical analysis was done in Graphpad Prism. The type of statistical test is 
indicated in the figure legend for each experiment. p-Values < 0.05 were considered 
significant.  
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3 RESULTS 
To test our hypothesis we first wanted to investigate if it is mechanistically possible to 
induce cell death in podocytes by sustained TRPC5 activation. We used riluzole, a 
drug used for treatment of amyotrophic lateral sclerosis with unknown mechanism 
(Bellingham, 2011), which was recently identified as a specific TRPC5 activator 
(Richter et al., 2014). To be able to investigate the effects of TRPC5 activation 
specifically in podocytes we used the podocyte cell line established by our 
collaborator Dr. Mundel (Mundel et al., 1997).  
 
3.1 TRPC5 activation causes podocyte death 
TRPC5 activation with riluzole causes cell death in a dose and time dependent 
manner (Fig. 1A-C). The Luminescent Cell Viability Assay measuring ATP content 
(Fig. 1A) and annexin V & propidium iodide  (PI) staining measuring membrane 
integrity (Fig. 1 B/C) both showed increasing cell death with increasing dose or time 
of exposure to riluzole. To verify that the riluzole effects are mediated by TRPC5 
activation we used ML204, a specific TRPC5 blocker (Miller et al., 2011). By blocking 
TRPC5 30min prior to and during the incubation with riluzole we could protect 
podocytes from riluzole induced cell death. ML204 alone had no effect on survival. 
To keep the culture condition the same over the time course of the experiment and 
replenish potentially degraded or metabolized drugs we changed media every 3rd 
day. Because dead cells disintegrate or loose adherence to the dish during media 
changes, the number of surviving (Annexin&PI negative) cells is given. (Fig. 1D) At 
100µM riluzole podocyte death becomes apparent by phase contrast microscopy 
after three days while podocytes incubated with riluzole and ML204 or ML204 alone 
look healthy. (Fig. 1E) These results establish that sustained TRPC5 activation 
causes podocyte death. 
Results 
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Figure 1: TRPC5 activation induces podocyte death. (A) Podocytes were incubated with the indicated 
doses of TRPC5 activator riluzole for two or three days. Cell survival was measured via ATP content 
with the Promega CellTiter-Glo® Luminescent Cell Viability Assay according to the manufactures 
protocol. p<0.005 for all differences except 100µM riluzole:2d vs. 100µM riluzole:3d, 100µM riluzole:3d 
vs. 200µM riluzole:2d and 300µM riluzole:2d vs. 300µM riluzole:3d. Error bars show confidence 
interval (CI) (B) Podocytes were incubated with escalating doses of riluzole for two days. Relative 
amount of dead (Annexin and/or PI positive) cells was measured by flow cytometry. p<0.05 for all 
differences except 100 vs. 200µM riluzole. Error bars show CI (C) Podocytes were incubated for 
increasing times with 200µM riluzole. Cell death was determined with Annexin&PI by flow cytometry. 
For each time point the percentage of dead cells in the riluzole sample subtracted by the percentage 
of dead cells in the control is shown to control for natural turnover. All differences between the groups 
are significant with p<0.001. Error bars show CI (D) To show that riluzole is activating TRPC5 
specifically we preincubated podocytes with the TRPC5 blocker ML204 followed by parallel incubation 
with riluzole and ML204 for nine days. Media was changed and replaced with fresh media and drugs 
every 3rd day. The number of surviving cells measured by flow cytometry shows that TRPC5 blockade 
is protecting against riluzole induced cell death. Error bars show standard deviation (SD) (E) Phase 
contrast images taken from the same experiment at day 3. Podocytes incubated with riluzole are dying 
and detaching from the dish while podocytes incubated with riluzole and ML204 are protected. All 
statistical analysis was done with ANOVA and Tukey post-test. 
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3.2 TRPC5 activation leads to mitochondrial permeability transition 
To investigate the role of MPT in the riluzole induced podocyte death we used the 
calcein and cobalt (Co2+) staining (Vaseva et al., 2012). Co2+ is quenching the calcein 
fluorescence everywhere except in the mitochondrial matrix because it is not able to 
permeate through the intact inner mitochondrial membrane. If the MPT pore opens, 
Co2+ diffuses into the mitochondria causing a decrease in calcein fluorescence. We 
used Life Technologies MitoProbe Transition Pore Assay Kit and its adapted protocol 
for our experiments. Incubation with 200µM riluzole for 24h decreased calcein 
fluorescence to the level of the positive control for MPT (Fig. 2A). This suggests a 
lethal loss of mitochondrial membrane integrity. When the MPT pore is open, an 
increase in ROS either as cause or consequence of MPT has been observed (Rasola 
and Bernardi, 2011). Using the ROS indicator H2DCFDA we could see an increase 
after podocyte treatment with Riluzole (Fig. 2B). Additionally we could confirm this 
result using the more specific mitochondrial superoxide indicator Mitosox Red (Fig. 
2C). Similar to rates of cell death due to Riluzole (Fig. 1A/B and F), MPT was 
observed in a dose-dependent manner. (Fig. 2D). To show the riluzole induced MPT 
is specifically mediated by TRPC5 we used ML204 to block TRPC5. As shown in Fig. 
2 D and E the calcein fluorescence is rescued after ML204 treatment. These data 
suggest MPT as an important mechanism for podocyte death induced by sustained 
TRPC5 activation. 
 
3.3 TRPC5 activation induces mitochondrial swelling and fragmentation.  
Swelling of the mitochondrial matrix is a morphologic characteristic of MPT (Rasola 
and Bernardi, 2011). Fragmentation is a common mitochondrial response to damage 
ranging from ischemia reperfusion injury to high glucose (Brooks et al., 2009; Yu et 
al., 2006). Mitochondria fuse or fragment in response of different environmental 
stresses. Hyperfusion is seen in response to increased energy demand. The idea is 
similar to an electrical grid. A long interconnected network is efficiently distributing 
energy in the cell. Mitochondria use a proton gradient over their inner membrane to 
produce ATP. This gradient can be established anywhere along the membrane. Thus 
protons can be pumped out of the mitochondrial network in the periphery of the cell 
where necessary oxygen is abundant and used to produce ATP closer to where its 
needed in more central regions of the same network (Tondera et al., 2009; 
Westermann, 2010; Youle and van der Bliek, 2012). Fragmentation occurs in 
consequence of direct mitochondrial damage. If only parts of the mitochondrial 
network are damaged this is a way to facilitate quality control by separating and 
degrading the damaged mitochondria (Westermann, 2010; Youle and van der Bliek, 
2012). While working with thapsigargin (Thg) to establish our assays for 
mitochondrial morphology we were able to confirm this. Low doses of Thg (3µM) 
cause a strong and finally fatal unfolded protein response. In this experiment even 
podocytes close to death after three days of exposure showed no fragmentation but 
highly elongated, hyperfused mitochondria. In contrast podocytes incubated with 
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20µM Thg for 24h, which causes direct mitochondrial damage with MPT (Korge and 
Weiss, 1999) showed extensive swelling and fragmentation (Fig. 3). 
 
Figure 2: TRPC5 activation induces Mitochondrial Permeability Transition (MPT) in podocytes. (A) 
Podocytes were incubated for 24h with 200µM riluzole before being stained with calcein and Co2+ and 
analyzed by flow cytometry. A decrease in calcein fluorescence means the MPT pore has opened and 
Co2+ can get into the mitochondria quenching the calcein fluorescence there. The ionophore 
ionomycin was used as positive control to induce MPT by maximally increasing cytosolic Ca2+. The 
value of each sample is the average calcein fluorescence of 30000 to 50000 cells measured by flow 
cytometry. Pooled relative values of three experiments done in triplicate are shown. Error bars indicate 
SD. *p=2.8E-07, t-test (B) Riluzole is increasing reactive oxygen species (ROS). Increased 
fluorescence of the ROS indicator H2DCFDA was measured by flow cytometry. Tert-butyl 
hydroperoxide was used as positive control (data not shown because of scale at 8.5±1.6) Error bars 
indicate CI.  **p=6E-05, t-test (C) Riluzole is increasing mitochondrial superoxide. Increased 
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fluorescence of the specific mitochondrial superoxide indicator Mitosox was measured by flow 
cytometry. H2O2 was used as positive control. Error bars indicate SD.  ***p=0.0002, t-test (D) 100µM 
riluzole is causing a 10% decrease in calcein fluorescence after three days. The much more delicate 
phenotype is correlating well with the observed different timeframe between 200 and 100µM riluzole in 
causing cell death (almost all cells dead after 3-4 days at 200 vs. 50% surviving after 9 days at 100, 
Fig. 1). Error bars indicate SD.  p-values are calculated by ANOVA with Tukey post-test (E) The same 
10% decrease in calcein fluorescence can been seen already after two days by incubating the cells 
with riluzole during the staining process. Calcein fluorescence is higher with ML204. p-values are 
calculated by ANOVA with Tukey post-test (F) The number of surviving cells counted in parallel to the 
MPT assay at three days shows a significant decrease with riluzole. #p<0.005 to all others, all other 
conditions show no statistically significant differences. ANOVA with Tukey post-test, Error bars show 
CI.  
  
 
 
Figure 3 Mitochondrial morphology changes in response to stress. (A) Podocytes were incubated with 
3µM thapsigargin (thg) for three days to cause a lethal unfolded protein response. While the cells are 
close to death at this time point their mitochondria maintain elongated hyperfused morphology. (B) To 
introduce direct mitochondrial damage and MPT podocytes were incubated with 20µM thg for 24h. In 
this condition the mitochondria show characteristic swelling and fragmentation. 
 
Podocytes incubated with 200µM riluzole for 24h showed mitochondrial swelling and 
fragmentation (representative images are shown in Fig. 3A). To be able to visualize 
mitochondrial dynamics in living cells we used MitoTracker® Red CM-H2XRos to 
stain mitochondria before starting the experiments. After incubating with riluzole for 
the indicated times we took the podocytes right out of the incubator to the 
microscope without any further manipulation. This is necessary because we noticed 
the morphologic change is reversible within a short timeframe. Live imaging revealed 
that mitochondrial swelling and fragmentation is reversed in the absence of riluzole 
within 30min. (Fig. 3B). However this only seems to be the case for up to 48h with 
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200µM riluzole. After 24h incubation with 300µM riluzole the podocytes already had 
crossed a point of no return and their mitochondria stayed swollen and fragmented 
even after incubating them with fresh media (Fig. 3C). These observations by live 
microscopy further corroborate that sustained TRPC5 activation causes 
mitochondrial damage leading ultimately to podocyte death. 
 
3.4 TRPC5 activation leads to podocyte loss in vivo 
To validate these in vitro findings, we sought to study an animal model of progressive 
proteinuric CKD. Rats that overexpress the human Angiotensin II receptor type 1 
(hAGTR1) specifically in podocytes (AGTR1 TG rats) spontaneously develop 
proteinuria, nephrotic syndrome and podocyte loss resulting in glomerulosclerosis, 
independent of changes in blood pressure, at the age of 15 weeks. They finally die 
from renal failure at 60 weeks (Hoffmann et al., 2004). TRPC5 is activated 
downstream of AGTR1 to initiate cytoskeletal rearrangements (Tian et al., 2010). 
Therefore we hypothesized that sustained TRPC5 activation in the AGTR1 TG rats is 
causing similar effects to the observed sustained TRPC5 activation with riluzole in 
vitro. Podocyte loss in the AGTR1 TG rat may be due to Ca2+ overload and 
mitochondrial damage with MPT, thus we specifically hypothesized that it should thus 
be beneficial to block the Ca2+ influx through TRPC5 in vivo.  
In an initial study, we treated AGTR1 TG rats with ML204 for two weeks after onset 
of disease marked by increasing albuminuria. The albuminuria remitted significantly 
under ML204 treatment. 
This study reveals TRPC5 activity as critical mediator of disease progression in CKD 
and suggests TRPC5 blockade as new therapeutic strategy for acquired and 
progressive proteinuric kidney disease.  
Results 
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Figure 4: Riluzole induces mitochondrial swelling and fragmentation. Mitochondria were stained using 
MitoTracker Red before the start of the experiment. The dye forms conjugates with proteins inside 
mitochondria, which result in stable staining for up to three days in podocytes. All images were 
acquired by confocal microscopy from living podocytes in cell culture media with a 63X water 
immersion lens. (A) Podocytes incubated for 24h with 200µM riluzole show characteristic 
mitochondrial swelling and fragmentation. We quantified mitochondrial swelling by counting all 
mitochondria above certain minimum size and circularity. To quantify fragmentation we used the 
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aspect ratio (ratio of minor axis to major axis of the best fitting ellipse) for all mitochondria. All images 
are at the same magnification and were analyzed with ImageJ. *p=0.02, ** p=0.0007, t-test, error bars 
show SD. (B) Even after 48h incubation with 200µM riluzole mitochondrial swelling and fragmentation 
is still reversible within a short timeframe. Two representative images of the same podocyte are 
shown. After taking the first image the riluzole containing media was replaced with fresh media without 
riluzole. Within 30min the mitochondrial structure seemed almost normal. (C) In contrast cells 
incubated with 300µM riluzole for 24h sowed irreversible changes mitochondrial shape. In this 
experiment we acquired the images in fresh media without riluzole. The pictures were then analyzed 
with the same algorithms as used in (A). ***p=0.0001, ****p=4.2E-21 Error bars show CI. The graphs 
show pooled data of three experiments done in triplicate with four pictures taken randomly for each 
sample. This equals several thousand measured mitochondria for each condition.  
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4 DISCUSSION 
 
In this study we show that TRPC5 activation with riluzole causes podocyte death by 
Ca2+ toxicity initiating mitochondrial damage and MPT. We could show in two 
independent assays that TRPC5 activation with riluzole leads to podocyte death in a 
dose and time dependent manner. Further we show that it is possible to protect 
podocytes from the detrimental effects of chronic TRPC5 activation with a novel 
TRPC5 blocker ML204. Podocyte loss is the critical step in the development of 
irreversible glomerulosclerosis (D'Agati et al., 2011). We suspect that continuous 
TRPC5 activation in a chronic disease scenario leads to podocyte loss to a point of 
no return with irreversible glomerulosclerosis. Therefore blocking TRPC5 might prove 
to be a valuable therapeutic strategy.     
 
4.1 Transient receptor potential channels in chronic kidney disease 
We show further evidence that Ca2+ signaling in podocytes plays a major role in 
kidney disease progression. Activating mutations in TRPC6 (a Ca2+-channel closely 
related to TRPC5) are known to cause hereditary FSGS in patients (Winn et al., 
2005). What role which channel plays in kidney disease progression will need further 
genetic studies. A major problem with TRPC6 as potential therapeutic target is its 
prominent role in the cardiovascular system (Dietrich et al., 2005). Interestingly while 
the TRPC6 KO mouse suffers from elevated systemic blood pressure, 
overexpressing TRPC6 in mouse hearts causes pathological remodeling culminating 
in lethal heart failure (Kuwahara et al., 2006). This highlights an important 
homeostatic role of TRPC6. In podocytes this homeostatic role of TRPC6 is 
increasingly apparent as well (Wieder and Greka, 2016). TRPC5 is known to regulate 
the cytoskeletal rearrangement leading to foot process effacement in podocytes 
(Schaldecker et al., 2013). If and how foot process effacement progresses to 
glomerulosclerosis is still under debate (D'Agati et al., 2011; Kriz et al., 2013). It 
could already be shown in cancer cells and neurons that sustained activation of 
TRPC5 leads to calcium toxicity and cell death (Akbulut et al., 2015; Carson et al., 
2015; Hong et al., 2015). Our data shows this for podocytes. Notably the TRPC5 
blocker ML204 was able to improve outcome in a Huntington’s disease mouse model 
(Hong et al., 2015). To get an idea of possible side effects off a TRPC5 blocking 
therapy it is worth to look at the TRPC5 knockout mouse. The only initially apparent 
phenotypes were restricted to the central nervous system resulting in a diminished 
innate fear response (Riccio et al., 2009). However, a recent publication unveiled that 
the TRPC5 knockout mouse has a defunct baroreceptor response leading to severe 
blood pressure fluctuations and an increased mean arterial blood pressure. Even 
though the baroreceptor response was abnormal it was not abolished. The authors 
conclude that TRPC5 is only one of multiple mechanosensors in baroreceptor 
neurons (Lau et al., 2016). Additionally all chronic kidney disease patients who could 
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benefit from TRPC5 blockade should receive an ARB (angiotensin receptor blocker) 
or ACE-I (angiotensin-converting enzyme inhibitor) in any case and most of them will 
be on additional anti-hypertensive medication as well as part of the standard of care 
(Stevens et al., 2013). Therefore we believe TRPC5 blocking drugs could be a 
valuable addition to the treatment regimen for chronic kidney disease.  
 
4.2 Mitochondrial damage in chronic kidney disease 
Mitochondrial function is increasingly recognized as one of the critical pillars of 
podocyte homeostasis. Maintaining the podocytes sophisticated adaptive 
cytoskeletal structure in the mechanically highly demanding environment of the 
glomerulus requires a lot of energy. This energy is almost exclusively provided by the 
mitochondrial respiratory chain in podocytes (Muller-Deile and Schiffer, 2014). 
Similar to the well-known mutations in slit diaphragm and cytoskeletal proteins, 
mutations in mitochondrial proteins lead to early onset steroid resistant nephrotic 
syndrome (Ashraf et al., 2013). Calcium influx through TRPC5 is capable of initiating 
several different cell death pathways. Thus for instance based on work on TRPC5 
initiated calcium toxicity in neurons an additional activation of the calpain-caspase 
pathways seems likely (Hong et al., 2015). However, knowing that mitochondrial 
damage in podocytes leads to kidney disease in humans (Malaga-Dieguez and 
Susztak, 2013), makes us confident that our observation of sustained TRPC5 
activation causing mitochondrial damage and podocyte death is relevant for human 
disease.  
 
4.3 Cell-to-cell variability  
TRPC5 activation by 100µM riluzole produced a slow but continuous rate of podocyte 
death. This in vitro finding may be relevant to chronic, incremental disease 
progression in vivo. Interestingly, our data suggest that only a fraction of the 
podocyte population undergoes MPT at any given time after TRPC5 activation with 
100µM riluzole. This can be explained by cell-to-cell variability (Spencer et al., 2009). 
In this publication the authors show that, within hours of their division the response of 
two daughter cells to an apoptotic stimulus differs significantly. Genetically and 
epigenetically those cells are identical because they originate from one mitosis. In 
further experiments the authors show that small differences in protein concentrations 
can explain this effect. All the observed differences in protein concentrations were 
within the expected distributions so that it proved to be impossible to predict the cells 
response based on single protein concentration measurement. Thus the seemingly 
binary process of cells surviving or dying is spread out over a long timeframe for the 
population with only a small number of cells dying at any given time point after the 
insult. In a similar fashion the Ca2+ buffering capacity is higher in some podocytes 
than others, allowing them to survive longer, even during prolonged periods of 
TRPC5 activation. Thus while the average number of surviving cells drops below 
55% after incubation with 100µM Riluzole only a small fraction of cells undergoes 
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MPT at any given time. This together with the fact that a lot of the early effects we 
see after TRPC5 activation are reversible makes us hopeful that TRPC5 blockade 
can be a successful therapeutic strategy in early-diagnosed acquired proteinuric 
kidney disease.  
 
4.4 TRPC5 blocking agents in vivo 
The encouraging results of this study resulted in a trial of TRPC5 blocking agents in a 
rat model of CKD. Rats overexpressing the human angiotensin receptor type 1 
(AT1R) specifically in podocytes show progressive signs of CKD including proteinuria 
and podocyte loss before they die of kidney failure at an age of 60 weeks (Hoffmann 
et al., 2004). TRPC5 activity increased in concert with disease progression and 
treatment with TRPC5 blockers in rats with established disease ameliorated 
proteinuria and prevented podocyte loss. These data indicate that in vivo TRPC5 is 
viable target for CKD treatment. 
 
4.5 Conclusion  
Our data provide the first evidence that TRPC5 blockers may be a successful 
therapeutic strategy for proteinuric CKD. In our hands, ML204 treatment showed no 
significant adverse effects even at high doses, in line with past findings in TRPC5 KO 
mice, which primarily showed a diminished fear response (Riccio et al., 2009). Given 
that 20 million Americans and millions more worldwide (Levey et al., 2007) are 
suffering from CKD, an anti-proteinuric drug with putative anxiolytic side effects 
appears attractive. 
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5 SUPPLEMENT 
5.1 Aspect ratio ImageJ script: 
macro "mitoAR [F6]" { 
run("Convolve...", "text1=[0 0 -1 -1 -1 0 0\n0 -1 -3 -3 -3 -1 0\n-1 -3 0 7 0 -3 -1\n-1 -3 7 
24 7 -3 -1\n-1 -3 0 7 0 -3 -1\n0 -1 -3 -3 -3 -1 0\n0 0 -1 -1 -1 0 0\n] normalize"); 
setAutoThreshold("Default dark"); 
setThreshold(100, 255); 
run("Analyze Particles...", "size=0.5-Infinity circularity=0.00-1.00 show=[Bare 
Outlines] display exclude summarize in_situ"); 
} 
 
 
5.2 Mitochondrial swelling ImageJ script: 
macro "mitoswelling [F5]" { 
run("Convolve...", "text1=[0 0 -1 -1 -1 0 0\n0 -1 -3 -3 -3 -1 0\n-1 -3 0 7 0 -3 -1\n-1 -3 7 
24 7 -3 -1\n-1 -3 0 7 0 -3 -1\n0 -1 -3 -3 -3 -1 0\n0 0 -1 -1 -1 0 0\n] normalize"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
setThreshold(101, 255); 
run("Analyze Particles...", "size=1.1-Infinity circularity=0.55-1.00 show=Masks display 
exclude include summarize in_situ"); 
} 
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7 POSTER ABSTRACT 
 
for the American Society of Nephrology Kidney Week 2014 Annual Meeting, 
November 13-16 in Philadelphia: 
 
 
TRPC5-mediated podocyte calcium toxicity drives progressive glomerular disease 
 
Frank Dubois, Philip Castonguay, Sookyung Kim, Jonas Sieber, Astrid Weins & Anna Greka 
 
 
Background: Podocyte injury, with proteinuria as the earliest sign, is the critical step in various forms 
of kidney disease. Podocyte-specific expression of the human angiotensin receptor type 1 (AT1R) in 
rats (AT1R TG rats) causes progressive podocyte damage and loss, leading finally to kidney failure 
and death after 40-50 weeks. Our laboratory established that deletion or pharmacological blockade of 
TRPC5 channels is protective in acute models of filter barrier damage, but the role of TRPC5 in in 
disease progression remains unknown. Previously we have also shown that AT1R activation promotes 
TRPC5-mediated cytoskeletal disruption in podocytes.  
Methods: We investigated the influence of TRPC5 on disease progression in AT1R TG rats by 2-
week treatment with the TRPC5 inhibitor ML204, starting after proteinuria had developed. For 
mechanistic studies, we activated TRPC5 pharmacologically in conditionally immortalized mouse 
podocytes after 11 days of differentiation. Annexin V/PI labeling was used as cell death assay, and 
mitochondrial permeability transition (MPT) was measured with Calcein/Co2+. Analysis was done by 
flow cytometry. 
Results: Treatment with the TRPC5 blocker ML204 decelerated disease progression in the AT1R TG 
rats. Specifically, albuminuria remitted under ML204 treatment. In vivo, podocytes showed signs of 
recovery following treatment. Mechanistically, we show that sustained TRPC5 activation leads to 
podocyte calcium toxicity via MPT and finally cell death, in a dose and time dependent manner. These 
effects can be blocked effectively by ML204. 
Conclusion: This study reveals sustained TRPC5 activation as a driving force in progressive 
glomerular disease. Mitigated disease progression by ML204 treatment in AT1R TG rats is an 
important proof of concept study for the potential of TRPC5 blockade as a therapeutic strategy in 
progressive proteinuric kidney diseases 
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10 SUMMARY 
 
Chronic kidney disease is a major cause of mortality and morbidity worldwide. 
Damage to the filter barrier formed by the podocytes in the kidney is a critical step of 
kidney disease. Podocytes are terminally differentiated cells, which cannot be 
replaced in adults. If enough podocytes are lost the kidney function breaks down. 
The complex cytoskeletal arrangement necessary to create the filter structure is 
regulated by calcium currents through transient receptor potential channels. One of 
earliest clearly visible sign of podocyte damage is the cytoskeletal rearrangement 
known as foot process effacement. Transient receptor potential channel 5 (TRPC5) 
has recently been show to play an essential role in the initiation of this process. 
However, the role of TRPC5 in disease progression remains unknown. We 
hypothesized that the continuous calcium influx caused by sustained TRPC5 
activation, as in a chronic disease setting, could lead to calcium toxicity and podocyte 
death.  
  
To test this hypothesis, we activated TRPC5 pharmacologically in conditionally 
immortalized mouse podocytes. We used cell viability assays, confocal microscopy, 
and flow cytometry to examine the relationship between TRCPC5 activation and cell 
death and mitochondrial damage typical for calcium toxicity.   
  
Our results showed that sustained TRPC5 activation can lead to irreversible 
podocyte injury and death in a dose and time dependent manner. Exploring the 
underlying mechanisms we observed signs of mitochondrial damage, as a result of 
sustained TRPC5 activation. These included mitochondrial swelling, fragmentation, 
increased production of reactive oxygen species and mitochondrial permeability 
transition leading to irreversible damage to the podocytes.  
  
This study revealed that sustained TRPC5 activation leads to podocyte death by 
Calcium toxicity initiating mitochondrial damage and mitochondrial permeability 
transition. Further we show that it is possible to protect podocytes from the 
detrimental effects of chronic TRPC5 activation with a novel TRPC5 blocker ML204. 
Podocyte loss is the critical step in the development of irreversible glomerulosclerosis 
causing chronic kidney disease. We suspect that continuous TRPC5 activation in a 
chronic disease scenario leads to podocyte loss up to a point of no return with 
irreversible glomerulosclerosis. Therefore blocking TRPC5 might prove to be a 
valuable therapeutic strategy. One of the major advantages of TRPC5 as therapeutic 
target is the fact that it is only expressed in the kidney and in the nervous system. 
The TRPC5 knockout mouse therefore has no major health impairment. A TRPC5 
blocking drug, which could stop the progression of chronic kidney disease, thus 
seems a promising possibility.  
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